Search Results

Further advancements in Europe and the US increase capacity and process efficiency ● Construction of new clinical manufacturing facility in Des Plaines on schedule ● Established Skokie site with ongoing strong performance for biotech partners ● Infrastructure upgrades at Austrian site further streamline customers’ path to clinic

Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.

As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.

BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.

Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan

Strategic Saudi partnership with Rawafed Health International Company targets one of the region’s largest diabetes and injectable-therapy markets, supported by leading healthcare infrastructure, pharmacy access in the region

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.